Entecavir, a drug approved by the Food and Drug Administration for the treatment of chronic hepatitis B virus (HBV) infection, is not believed to inhibit replication of human immunodeficiency virus ...

Of entecavir-treated patients, 19% achieved undetectable HBV DNA levels versus 1% in the LVD-treated group (p < 0.0001) and 61% in the entecavir group achieved normalization of ALT versus 15% in ...

Dublin, April 30, 2024 (GLOBE NEWSWIRE) -- The "Entecavir Market Size, Forecast, and Market Insight - 2032" report has been added to ResearchAndMarkets.com's offering.A thorough market analysis on ...

Entecavir, currently in Phase III clinical development, is an investigational oral nucleoside analogue discovered at Bristol-Myers Squibb which is a selective inhibitor of the hepatitis B virus.

Entecavir exhibits potent antiviral activity, with a 50% effective concentration more than 300-fold greater than that of lamivudine in vitro. [14, 15] In multinational phase II and III clinical ...

A two-year trial of entecavir followed by lamivudine in patients with chronic hepatitis B virus (HBV) infection resulted in a virologic rebound rate of 24 percent and 12 percent drug-resistance ...

A dual regimen of entecavir (Baraclude) plus tenofovir (Viread) for 48 weeks led to virological response and was generally well-tolerated among people with chronic hepatitis B who had experienced ...

The anti-hepatitis B drug entecavir (Baraclude) should not be prescribed to HIV-positive individuals unless they are taking potent anti-HIV therapy, the US Food and Drug Administration (FDA) and maker ...

Drug Name : Entecavir Entecavir (Baraclude) generic is an oral antiviral agent, prescribed for hepatitis B. It works by decreasing the amount of hepatitis B virus (HBV) in the body.

The Committee discussed the clinical effectiveness of entecavir in treating chronic hepatitis B and considered all of the available evidence. It acknowledged that in RCTs entecavir had been ...

Of these, 1,205 without HCC within the first 5 years of entecavir/tenofovir therapy were followed for 5 to 10 years (median, 6.8 years).

The manufacturer approached the initial decision problem by comparing entecavir monotherapy with interferon alfa-2a and -2b, peginterferon alfa-2a, lamivudine, adefovir dipivoxil and telbivudine. The ...